glp-1 agonists receptor show promise in treating substance use disorders GLP-1 receptor agonists for individualized
Description
Purpose of Review The development of long-acting incretin receptor agonists represents a significant advance in the fight against the concurrent epidemics of type 2 diabetes mellitus (T2DM) and obesity
Conclusions We found no signal of disproportionate reporting of an association between GLP-1RA use and SSIBs
The key takeaway
GLP-1/GIP Therapy Discontinuation: Why the How Matters One of the most-discussed challenges with GLP-1/GIP agonists such as tirzepatide (Mounjaro) is weight regain after stopping therapy
This means your body can actually use what youre takingan often overlooked but essential factor in real-world results
